192 related articles for article (PubMed ID: 15385933)
21. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
Ferreira LV; Souza SA; Arnhold IJ; Mendonca BB; Jorge AA
J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
[TBL] [Abstract][Full Text] [Related]
23. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
[TBL] [Abstract][Full Text] [Related]
24. Mutations in PTPN11 are rare in adult myelodysplastic syndromes and acute myeloid leukemia.
Watkins F; Fidler C; Boultwood J; Wainscoat JS
Am J Hematol; 2004 Aug; 76(4):417. PubMed ID: 15282682
[No Abstract] [Full Text] [Related]
25. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
26. Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients.
Roumier C; Lejeune-Dumoulin S; Renneville A; Goethgeluck AS; Philippe N; Fenaux P; Preudhomme C
Leukemia; 2006 Mar; 20(3):433-6. PubMed ID: 16424869
[TBL] [Abstract][Full Text] [Related]
27. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
Tartaglia M; Mehler EL; Goldberg R; Zampino G; Brunner HG; Kremer H; van der Burgt I; Crosby AH; Ion A; Jeffery S; Kalidas K; Patton MA; Kucherlapati RS; Gelb BD
Nat Genet; 2001 Dec; 29(4):465-8. PubMed ID: 11704759
[TBL] [Abstract][Full Text] [Related]
28. Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation.
Shimada H; Shima H; Shimasaki N; Yoshihara H; Mori T; Takahashi T
Ann Oncol; 2005 Aug; 16(8):1400. PubMed ID: 15857842
[No Abstract] [Full Text] [Related]
29. Common acute lymphoblastic leukemia in a girl with genetically confirmed LEOPARD syndrome.
Laux D; Kratz C; Sauerbrey A
J Pediatr Hematol Oncol; 2008 Aug; 30(8):602-4. PubMed ID: 18799937
[TBL] [Abstract][Full Text] [Related]
30. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
31. Respiratory failure, juvenile myelomonocytic leukemia, and neonatal Noonan syndrome.
Cheong JL; Moorkamp MH
J Pediatr Hematol Oncol; 2007 Apr; 29(4):262-4. PubMed ID: 17414570
[TBL] [Abstract][Full Text] [Related]
32. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
33. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
[TBL] [Abstract][Full Text] [Related]
34. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome.
Yoshida R; Hasegawa T; Hasegawa Y; Nagai T; Kinoshita E; Tanaka Y; Kanegane H; Ohyama K; Onishi T; Hanew K; Okuyama T; Horikawa R; Tanaka T; Ogata T
J Clin Endocrinol Metab; 2004 Jul; 89(7):3359-64. PubMed ID: 15240615
[TBL] [Abstract][Full Text] [Related]
35. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
Lee ST; Ki CS; Lee HJ
Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
[TBL] [Abstract][Full Text] [Related]
36. PTPN11 mutations and genotype-phenotype correlations in Noonan and LEOPARD syndromes.
Ogata T; Yoshida R
Pediatr Endocrinol Rev; 2005 Jun; 2(4):669-74. PubMed ID: 16208280
[TBL] [Abstract][Full Text] [Related]
37. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
Gratias EJ; Liu YL; Meleth S; Castleberry RP; Emanuel PD
Pediatr Blood Cancer; 2005 Feb; 44(2):142-6. PubMed ID: 15390271
[TBL] [Abstract][Full Text] [Related]
38. Gene transfer of SHIP-1 inhibits proliferation of juvenile myelomonocytic leukemia cells carrying KRAS2 or PTPN11 mutations.
Metzner A; Horstmann MA; Fehse B; Ortmeyer G; Niemeyer CM; Stocking C; Mayr GW; Jücker M
Gene Ther; 2007 Apr; 14(8):699-703. PubMed ID: 17268534
[TBL] [Abstract][Full Text] [Related]
39. SHP-2 and myeloid malignancies.
Tartaglia M; Niemeyer CM; Shannon KM; Loh ML
Curr Opin Hematol; 2004 Jan; 11(1):44-50. PubMed ID: 14676626
[TBL] [Abstract][Full Text] [Related]
40. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.
Kratz CP; Niemeyer CM; Castleberry RP; Cetin M; Bergsträsser E; Emanuel PD; Hasle H; Kardos G; Klein C; Kojima S; Stary J; Trebo M; Zecca M; Gelb BD; Tartaglia M; Loh ML
Blood; 2005 Sep; 106(6):2183-5. PubMed ID: 15928039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
